Since IL-17, also called IL-17A, was identifi ed a decade ago from activated T cells, related cytokines, including IL-17B, C, D, E (also called IL- 25) , and F, have been reported and constitute the IL-17 cytokine family ( 1, 2 ) . IL-17, the best-studied member in this family, is a proinfl ammatory cytokine that was historically associated with many infl ammatory diseases, such as rheumatoid arthritis, asthma, lupus, and allograft rejection ( 1, 2 ) . In vitro, mRNA expression of genes encoding several chemokines (CCL2, CCL7, CXCL1, and CCL20 ) and matrix metalloproteinase 3 (MMP3) and MMP13 was signifi cantly up-regulated after IL-17 treatment ( 3 ). Moreover, IL-17 and TNF-␣ exhibit strong synergy in promoting infl ammatory gene expression ( 4 ) . In vivo, overexpressing IL-17 in the lungs resulted in chemokine upregulation and tissue infi ltration by leukocytes ( 3 ) . Conversely, inhibition of IL-17 signaling led to impaired host defense against bacterial infection ( 5 ) and resistance to autoimmune diseases ( 3, 6 -8 ) .
IL-17 binds to and signals through IL-17RA, a member of the IL-17R family ( 9 ) . Recently, it was reported that IL-17RA might form a heteromeric complex with IL-17RC ( 10 ) . IL-17 activates NF-B and the mitogen-activated protein kinase pathway ( 2 ) . IL-6 induction by IL-17 in mouse embryonic fi broblasts (MEFs) is dependent on TNFR-associated factor 6 (TRAF6) ( 11 ) . Recently, we identifi ed Act1 adaptor protein as an immediate and essential signaling component of IL-17RA ( 12 ) .
Recently, a new subset of Th cells named Th17 was identifi ed ( 13, 14 ) . The hallmark of Th17 subset is the production of IL-17. Interestingly, Th17 cells also express IL-17F, which shares the strongest homology to IL-17 ( 1, 2 ) . IL-17 and IL-17F genes are localized in the same chromosome region, and we previously found that this locus undergoes chromatin remodeling associated with Th17 diff erentiation ( 15 ) . Recently, an IL-17 -IL-17F heterodimer was found to be expressed in Th17 cells together anti -IL-17F (Fig. S1 A, available at http://www.jem.org/ cgi/content/full/jem.20071978/DC1), further supporting the specifi city of our antibody. After Th17 diff erentiation, almost all cells expressing IL-17 also expressed IL-17F ( Fig. 1 B ) , indicating that they are regulated by a similar molecular mechanism. However, there appears to be an IL-17F single-positive population, suggesting the existence of heterogeneous subpopulations in the Th17 lineage.
with IL-17 and IL-17F homodimers ( 16, 17 ) . IL-17F did not bind to IL-17RA in vitro ( 18 ) . However, an anti -IL-17RA antibody blocked IL-17F -mediated function, whereas IL-17RA -soluble protein did not ( 19 ) . IL-17RC was recently discovered to serve as a receptor for IL-17F ( 20 ) . However, the requirements of IL-17RA or IL-17RC in IL-17F signaling in vivo remain unclear.
IL-17F was reported to induce various cytokines, chemokines, and adhesion molecules in human airway epithelial cells, vein endothelial cells, and fi broblasts ( 21 ) . IL-17F was found in the airways of allergic asthma patients upon allergen challenge ( 22 ) . Interestingly, a mutation in the IL-17F gene was shown to be associated with human asthma and chronic obstructive pulmonary disease ( 21 ) . This literature suggests a linkage of IL-17F with human asthma. To analyze the function of IL-17F in airway infl ammation, adenoviral infection ( 23 ) or lipofectamine-mediated gene transfer ( 24 ) were adopted to acutely overexpress IL-17F in vivo, which resulted in the pulmonary recruitment of neutrophils.
In our current study, we have analyzed the expression, function, and signaling mechanisms of IL-17F. We demonstrate that IL-17 -expressing T cells also produce IL-17F protein. IL-17F regulates the expression of infl ammatory chemokines and cytokines, which is dependent on IL-17RA, Act1, and TRAF6 proteins. Lung-specifi c overexpresssion of IL-17F in mice leads to infi ltration of lymphocytes and macrophages and mucus production. The examination of IL-17 -and IL-17F -defi cient animals in multiple models has revealed the distinct requirements of these two genes in diff erent infl ammatory responses. Thus, IL-17F plays a critical role in the regulation of infl ammatory reactions.
RESULTS

Expression of IL-17F protein in IL-17 -expressing T cells
Although IL-17F has been shown to be coexpressed with IL-17 in Th17 cells, whether other IL-17 -expressing T cells in vivo also express IL-17F has not been clear. To allow measurement of IL-17F protein expression, we prepared a biologically active IL-17F -Ig fusion protein; we observed IL-6 or CXCL1 production in MEFs and peritoneal macrophages after IL-17F -Ig treatment (unpublished data). A polyclonal antibody against IL-17F was raised in rabbits. After affi nity purifi cation, we fi rst tested the polyclonal antibody by intracellular staining of 293T cells transfected with a mouse IL-17F expression vector. Anti -IL-17F stained IL-17F but not the vector transfectant ( Fig. 1 A ) . Moreover, this polyclonal antibody did not stain 293T cells expressing IL-17 ( Fig. 1 A ) . Thus, the antibody we raised appears to be specifi c for IL-17F.
To analyze IL-17F protein expression in diff erent Th subsets, we diff erentiated OT-II cells into Th1, Th2, and Th17 lineages. Using our anti -IL-17F antibody for intracellular staining, IL-17F protein was found expressed in Th17 cells that also expressed IL-17 but not in Th1 or Th2 cells ( Fig. 1 B ) . The protein expression of IL-17F was consistent with its mRNA expression (unpublished data). Excessive amounts of IL-17 inhibited staining by anti -IL-17 but not lamina propria and intestinal intraepithelium expressed IL-17F ( Fig. 1 D ) , but in these tissues, there existed a lot more IL-17 single-positive cells than Th17 cells generated in vitro and recovered from the CNS. Thus, analysis of IL-17F protein expression has revealed that IL-17F is generally coexpressed with IL-17 in T cells and has suggested the possibility of differential ratios of these two cytokines in diff erent T cell states or in diff erent tissues.
IL-17F regulates infl ammatory gene expression via IL-17RA, Act1, and TRAF6 We previously used a microarray analysis to identify the molecular targets of IL-17 and observed the up-regulation of chemokines and MMPs by IL-17 ( 3 ) . To address the biological function of IL-17F, we fi rst treated MEFs with IL-17F. We found that IL-17F induced CXCL1 , IL-6 , CCL2 , CCL7 , and MMP13 , similar to the action of IL-17 ( Fig. 2 A ) . The levels of gene expression induced by IL-17F were We also examined IL-17F expression in vivo. In addition to CD4 + T cells, it has been reported that IL-17 is also produced by ␥ ␦ T cells ( 25 ) . Also, during Mycobacterium tuberculosis infection, IL-17 production seems to be dominated by ␥ ␦ T cells ( 26 ) . In agreement with these studies, we found that splenic CD4 + and ␥ ␦ T cells expressed IL-17 upon activation ( Fig. 1 C ) . As seen in in vitro -generated Th17 cells, IL-17F was coexpressed with IL-17 in these cells, though there were some IL-17 single-positive cells.
In addition to Th17 cells generated in vitro, IL-17F was coexpressed with IL-17 in CD4 + T cells from the central nervous systems (CNS) of mice subject to the experimental autoimmune encephalomyelitis (EAE) model ( Fig. 1 D ) . Interestingly, most of the T cells that expressed IL-17F also expressed IL-17, and there were few IL-17 or IL-17F singlepositive cells. IL-17 + T cells have also been found constitutively in the lamina propria, dependent on IL-21, ROR ␥ t, and ROR ␣ ( 27 -29 ). We found that IL-17 hi CD4 + T cells in the Moreover, thymic stromal lymphopoietin, a molecule involved in allergic asthma and atopic dermatitis ( 30 ) , was induced by both IL-17 and IL-17F ( Fig. 2 A ) . Because thymic stromal lymphopoietin is a potent inducer of Th2 responses, typically more moderate than IL-17 at the concentration used (100 ng/ml). A detailed dose comparison of IL-17 versus IL-17F in IL-6 induction in MEFs also revealed that IL-17 is more potent than IL-17F (unpublished data). our result suggests a cross-regulatory mechanism of diff erent Th subsets.
To address which molecules may be used by IL-17F to initiate the signaling cascade, we fi rst prepared MEFs from IL-17RA -defi cient mice. Because TNF-␣ -or IL-1 ␤ -mediated IL-6 or CXCL1 productions were normal in IL-17RA -defi cient fi broblasts, IL-17 and IL-17F eff ects were both impaired in these cells ( Fig. 2 B ) . Moreover, injection of IL-17 or IL-17F into mouse peritoneum resulted in the recruitment of neutrophils within 4 h ( Fig. 2 B ) . In IL-17RA -defi cient mice, however, IL-17 and IL-17F both lost their ability to recruit neutrophils ( Fig. 2 B ) . These results indicate that IL-17RA is required for IL-17F as well as IL-17 signaling in vitro and in vivo.
IL-17 and IL-25 both use TRAF6 as their signaling intermediate ( 11, 31 ) . Recently we reported Act1 as an immediate adaptor protein downstream of IL-17RA ( 12 ) . We tested the requirement of these molecules in IL-17F -induced infl ammatory gene expression. Induction of CXCL1 was impaired in TRAF6 Ϫ / Ϫ MEFs upon IL-17F treatment ( Fig. 2 C ) . Also, although WT MEFs up-regulated the expression of IL-6, CXCL-1, and the transcriptional regulators CCAAT/enhancer binding protein ␦ and I B upon IL-17F treatment, Act1-defi cient MEFs did not ( Fig. 2 D ) . Our results thus indicate that similar to IL-17, IL-17F requires both Act1 and TRAF6 for its signal transduction leading to infl ammatory gene expression.
IL-17F overexpression induces airway infl ammation
IL-17F thus uses similar signaling mechanisms as IL-17 to regulate similar downstream genes. Because IL-17F has been implicated in airway infl ammation, we treated the mouse lung epithelial cell line MLE12 with IL-17F. IL-17F induced several chemokines in MLE12, as we found in MEFs ( Fig.  3 A ) . To understand the chronic eff ects of IL-17F function in vivo , we generated lung-specifi c transgenic mice that selectively overexpress IL-17F by epithelium cells using the Clara cell 10 ( CC10 ) gene promoter ( Fig. 3 B ) . Three founder lines were generated, and their off spring exhibited greatly increased IL-17F mRNA expression in the lung tissues ( Fig. 3 C ) and similar pathological symptoms. IL-17 mRNA expression in IL-17F transgenic mice remained unaff ected ( Fig. 3 C ) . Transgenic mice but not their control littermates developed abnormal lung pathology starting at 5 mo of age. Often, CC10 -IL-17F transgenic mice developed substantial infi ltration by macrophages ( Fig. 3 E ) . Also, similar to IL-17 transgenic mice, IL-17F transgenic mice exhibit peribronchial and perivascular infi ltration of CD4 + and B220 + lymphocytes ( Fig. 3 D ) . However, we did not observe any neutrophil recruitment in transgenic mice. Occasionally, in severe cases, transgenic mice were found with a CharcotLeyden -like crystal structure in the airway similar to that reported in the lung of IL-13 transgenic mice ( 32 ) ( Fig. 3 F ) . Increased mucus production was observed in lung tissues from transgenic mice via periodic acid Schiff (PAS) staining ( Fig. 3 G ) . The features of infl ammatory pathology and mucus production in CC10 -IL-17F mice are consistent with those observed in CC10 -IL-17 mice ( 3 ), supporting the idea that these two cytokines may have similar biological functions in vivo. Also, the infl ammatory genes up-regulated in MLE12 by IL-17F were also found signifi cantly up-regulated in CC10 -IL-17F mice ( Fig. 3 H ) .
Generation of IL-17 -and IL-17F -defi cient mice
To determine whether IL-17 and IL-17F have distinct functions in vivo, we generated and analyzed mice defi cient in IL-17 or IL-17F. IL-17 -defi cient mice were generated by gene targeting in embryonic stem cells by replacement of part of exon 2 with a luciferase-IRES-eGFP cassette without disrupting the splicing boundary (Fig. S2, A and B, available at http://www.jem.org/cgi/content/full/jem.20071978/DC1). The loxP-fl anked neomycin cassette was removed by crossing the heterozygous mice with CMV-Cre mice, and the resulting mice were intercrossed to generate homozygous KO mice. Compared with WT mice, IL-17 KO mice exhibited normal lymphoid compartments in both the thymus and spleen but moderately decreased percentages of CD4 + T cells in the spleen (P = 0.03; Fig. S2 , C and D). IL-17F KO was generated by an insertional inactivation of IL-17F exon 2 with an IRES-mRFP-polyA cassette (Fig. S3 A) . After removal of the puromycin-resistant gene in the mouse germline, heterozygous IL-17F KO mice were intercrossed to make homozygous animals, and PCR analysis of tail genomic DNA was used to analyze the genotypes (Fig. S3 B) . IL-17F Ϫ / Ϫ mice developed normally. Compared with WT mice, IL-17F KO mice exhibited normal CD4 + , CD8 + , and CD4 + CD8 + ratios in the thymus, and similar CD4 + , CD8 + , and B220 + populations in the spleen (Fig. S3, C and D) . CD11b + macrophage/ granulocyte, CD11c + CD11b lo dendritic cell, and CD4 + CD25 + regulatory T cell numbers were also compatible in IL-17F KO mice (Fig. S3 D) .
As a fi rst step to analyze these animals, IL-17F KO, IL-17 KO, and WT control mice were immunized with KLH in CFA. 7 d after immunization, the animals were killed and spleens were collected and restimulated with KLH. In ELISA analysis, IL-17F and IL-17 could not be detected in IL-17F KO and IL-17 KO splenocyte cultures, respectively ( Fig. 4 A ) . Intracellular cytokine staining also revealed no IL-17 and IL-17F expression in the corresponding animals (Fig. S1 B) . Levels of IL-17F were also reduced in IL-17 KO cells, whereas IL-17F defi ciency did not lead to a substantial reduction of IL-17 expression ( Fig. 4 A ) . IL-22 expression levels were moderately reduced in both IL-17F KO and IL-17 KO samples ( Fig. 4 A ) . In addition to T cell responses, KLHspecifi c Ig levels in sera from immunized IL-17F KO, IL-17 KO, and WT mice were determined by ELISA ( Fig. 4 B ) . Compared with WT mice, IL-17 -defi cient mice exhibited lower levels of IgM, total IgG, and all IgG subclasses tested, consistent with a previous paper on 2,4,6-trinitrochlorobenzene -challenged IL-17 -defi cient mice ( 33 ) , whereas IL-17F defi ciency resulted in a signifi cant increase of IgG2a levels, though IFN-␥ levels were not increased in these mice. These data suggest that IL-17F and IL-17 play important but perhaps diff erential roles in humoral immunity.
Differential requirements of IL-17 and IL-17F in autoimmune responses
To examine the functions of IL-17 and IL-17F in vivo, we fi rst used EAE, a Th17-mediated CNS infl ammation disease model. EAE was induced in WT, IL-17 KO, and IL-17F KO mice. IL-17 -defi cient mice were signifi cantly delayed in disease onset and progression, whereas IL-17F KO mice only showed moderately improved recovery compared with both WT and IL-17 KO mice ( Fig. 5 A ) . This indicates that IL-17 but not IL-17F is required for the initiation of neuronal infl ammation. When we examined infi ltrating mononuclear cells in the CNS, CD4 + cells were greatly reduced in both IL-17F KO and IL-17 KO compared with WT mice, whereas CD11b + cells were slightly increased in IL-17F KO animals ( Fig. 5 B ) . We then assessed the molecular basis for the reduced recruitment of T cells into the CNS in the mice deficient in IL-17F or IL-17 by real-time RT-PCR to assess chemokine expression in CNS tissue after induction of EAE. The expression of the chemokines CCL2 and CCL7 was greatly reduced in IL-17F KO compared with WT CNS, but more profoundly in IL-17 KO ( Fig. 5 C ) . CXCL1 expression was severely impaired in IL-17 KO but not in IL-17F KO in comparison with WT animals ( Fig. 5 C ) . To further understand whether IL-17F or IL-17 defi ciency aff ects the generation of autoreactive T cells, we assessed cytokine expression in splenocytes from the EAE mice upon myelin oligodendrocyte glycoprotein (MOG) peptide restimulation by ELISA. IFN-␥ expression levels were slightly increased in IL-17F KO but greatly elevated in IL-17 KO compared with WT cells ( Fig. 5 D ) . In comparison with WT splenocytes, IL-22 levels were slightly but not signifi cantly decreased in IL-17 but not in IL-17F KO mice, whereas IL-17 and IL-17F expression were not signifi cantly altered in IL-17F KO and IL-17 KO, respectively.
To better understand the diff erential eff ects of IL-17 and IL-17F on EAE pathogenesis, we immunized mice with MOG in CFA and analyzed cytokine expression by intracellular staining on day 7. At this early phase, the frequencies of IFN-␥ -expressing CD4 + T cells were elevated in the spleen but decreased in the draining lymph nodes in IL-17 KO compared with WT mice, whereas no diff erence was found in cells from IL-17F KO mice ( Fig. 5 E ) . The percentages of IL-17 + CD4 + cells were slightly decreased in both the spleens and draining lymph nodes from IL-17F KO in comparison to WT mice ( Fig. 5 E ) . In IL-17 KO mice, the frequencies of IL-17F + CD4 + cells were not altered ( Fig. 5 E ) . Our data thus indicate an eff ect of IL-17 but not IL-17F defi ciency in the priming phase, possibly resulting in a diff erent distribution of IFN-␥ + cells.
Differential functions of IL-17 and IL-17F in acute and chronic allergic airway responses
Because IL-17F has been implicated in allergic infl ammation in humans and mice, we subjected WT, IL-17 KO, and IL-17F KO mice to intranasal challenge by an allergenic fungal proteinase (FAP) derived from Aspergillus oryzae and analyzed these mice 18 h later. In this acute allergic response, consistent with a previous report ( 34 ) , signifi cant numbers of neutrophils were elicited by FAP in bronchoalveolar lavage fl uid (BALF) from WT mice as determined by CD11b and Gr-1 staining ( Fig. 6 A ) , or by May-Gr ü nwald-Giemsa staining of lavage cells (not depicted). IL-17F KO mice exhibited substantially reduced numbers of neutrophils. However, IL-17 KO mice had comparable numbers of neutrophils as the WT mice ( Fig. 6 A ) . Interestingly, IL-17RA KO mice had a similar reduction in neutrophils as IL-17F KO mice ( Fig. 6 A ) , indicating a requirement of IL-17RA in IL-17F -mediated neutrophilia in response to allergen challenge. To gain insight into the molecular mechanism underlying IL-17F -mediated neutrophil recruitment, we assessed the expression of neutrophil-attracting chemokines in the whole lungs by realtime PCR. Although many chemokines were elevated by allergen treatment in WT and two diff erent KO mice, expression levels of CXCL5 , a neutrophil-recruiting chemokine and one of the IL-17F target genes, were signifi cantly reduced in IL-17F KO but not IL-17 KO mice ( Fig. 6 B ) . This indicates that IL-17F may regulate neutrophil recruitment 
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KO mice exhibited increased phenotypes of CD11b int SSC lo , suggesting enhanced degranulation ( Fig. 6 D ) ( 36 ) . In support of this idea, RT-PCR analysis indicated that BALF cells from IL-17F KO mice expressed higher levels of major basic protein 1 and eosinophil peroxidase ( Fig. 6 D ) but not neutrophil-specifi c elastase (not depicted). These patterns were also observed by RT-PCR using total lung tissue RNAs (unpublished data).
Eosinophil degranulation is regulated by Th2 cytokines ( 36 ) . We asked whether IL-17F defi ciency might have an impact on type 2 cytokine expression. Lung lymph node cells from OVA-challenged IL-17F KO mice produced signifi cantly higher levels of IL-4, IL-5, and IL-13 than cells from WT and IL-17 KO mice upon ex vivo OVA restimulation ( Fig. 6 E ) . Splenocytes from IL-17 KO mice showed a greatly reduced production of IL-4, IL-5, and IL-13, whereas those in vivo by promoting CXCL5 induction in the lung in response to allergen.
Because IL-17 and IL-17F exhibited diff erential activities during innate responses to allergen challenge in the lung, we further investigated their roles in a chronic asthma model. WT, IL-17 KO, and IL-17F KO mice were immunized twice i.p. with OVA in aluminum hydroxide and subsequently challenged by intranasal administration of OVA protein in PBS. IL-17 KO mice receiving OVA had fewer BALF cells and eosinophils ( Fig. 6 C ) , which was consistent with previous studies using IL-17 or IL-17RA KO animals ( 33, 35 ) . On the other hand, there was no signifi cant diff erence in total BALF cell numbers between WT and IL-17F KO mice, but BALF cells from IL-17F KO mice had signifi cantly increased eosinophils when compared with IL-17 KO mice ( Fig. 6 C ) . FACS analysis revealed that eosinophils in IL-17F Results are mean ± SD. *, P < 0.05; and **, P < 0.01 using the Student ' s t test. n.s., not signifi cant.
from IL-17F KO mice exhibited enhanced IL-5 and IL-13 production ( Fig. 6 E ) . These analyses indicate that even though IL-17 positively regulates asthmatic allergic responses, especially Th2 cytokine production, IL-17F has a negative role and IL-17F defi ciency leads to greater Th2 cytokine expression and enhanced eosinophil function.
tissues from IL-17 KO mice exhibited the most severe epithelial lesion and crypt basal separation, consistent with a previous study using an anti -IL-17 monoclonal antibody ( 37 ) . In colon tissues from IL-17F KO mice, only mild damage was observed ( Fig. 7, B and C ) . Accordingly, there are more leukocytes in IL-17 -defi cient than WT lamina propria ( Fig. 7 B ) , consisting of a majority of macrophages together with neutrophils and lymphocytes, which was consistent with a previous study ( 38 ) . In a sharp contrast, IL-17F defi ciency led to greatly reduced infi ltrates in the lamina propria ( Fig. 7 B ) .
We investigated the molecular basis for diff erential recruitment of infl ammatory cells in the experimental animals by analysis of chemokine gene expression in colons using realtime RT-PCR. Unlike CXCL1 , which was similarly reduced in IL-17 KO and IL-17F KO mice, CCL2 , CCL5 , and CCL7 mRNA expression were elevated in IL-17 -defi cient mice upon DSS treatment when compared with WT mice, whereas
Differential function of IL-17 and IL-17F in dextran sulfate sodium (DSS) -induced colitis
The results on CNS and lung infl ammation indicate diff erential functions of IL-17 and IL-17F that target diff erent tissues. To further ascertain this fi nding, we subjected WT, IL-17 KO, and IL-17F KO mice to a colitis model induced by oral feeding with DSS (a compound from Gram-positive bacteria Leuconostoc species). Upon DSS treatment, WT mice developed acute colitis symptoms indicated by bloody diarrhea on days 2 -6, with a peak on days 3 -4 and loss of body weight from day 5. On day 8, the experimental mice were killed, and colon tissues were collected for histological and gene expression analysis. Compared with WT mice, IL-17 KO mice exhibited more severe diarrhea and more blood in the feces with increased weight loss, whereas IL-17F KO mice had much milder symptoms and less weight loss ( Fig. 7 A  and not depicted) . As revealed by histological analysis, colon found normal binding of IL-17F -Ig to IL-17RA Ϫ / Ϫ macrophages (unpublished data). Thus, IL-17RA may not directly mediate binding of IL-17F to the cell surface but rather may regulate its signaling with other receptor components. IL-17 signaling also requires IL-17RC, which forms a complex with IL-17RA ( 10 ). In our preliminary analysis, we found that siRNA reduction of IL-17RC expression in MEFs also decreased IL-17F -induced gene expression (unpublished data), suggesting the involvement of IL-17RC in IL-17F signaling. These results are consistent with a recent paper demonstrating the binding of IL-17F to IL-17RC ( 20 ) . Further studies are necessary to elucidate the receptors used by these cytokines. Although IL-17 and IL-17F may potentially bind to diff erent receptors on the target cells, they appear to use the same signaling components. In the current study, we for the fi rst time show the requirements of Act1 and TRAF6 in IL-17F induction of downstream infl ammatory genes.
In vitro , IL-17F appears to have a weaker proinfl ammatory function. One may predict that IL-17F may be less important than IL-17 in vivo. This may be true in the EAE model in which IL-17F is not required for the initiation of EAE with only a minor role in maintaining infl ammation in the CNS. Our results using IL-17F KO mice are consistent with our unpublished data that anti -IL-17F did not ameliorate EAE (unpublished data). In contrast, IL-17 KO mice, similar to mice treated with anti -IL-17 ( 3, 8 ) , exhibited greatly delayed onset and progression of EAE. Thus, IL-17 is thus a dominating pathogenic factor in EAE. However, our current study using mice defi cient in either the IL-17 or IL-17F gene has for the fi rst time provided a surprising insight into the diff erential function of these two cytokines in immune responses. During T cell priming in vivo in response to KLH or MOG peptide immunization, IL-17 -but not IL-17F -defi cient mice exhibited increased IFN-␥ expression in the spleen. Because IL-17 has not been found to regulate Th cell diff erentiation ( 39, 44 ) , this regulation may be indirect, for example, by acting on myeloid cells. On the other hand, IFN-␥ expression was found reduced in draining lymph nodes in these animals, suggesting a possibility that IL-17 regulates the localization of Th1 cells. In IL-17F -defi cient animals, IL-17 expression was reduced in the spleen although not signifi cantly in the lymph nodes. However, in the late phases of EAE, such a defect was not found, suggesting that IL-17F regulation of IL-17 expression could be overcome by chronic immune responses. Furthermore, IgG2a production was consistently upregulated only in IL-17F -defi cient animals. Because IFN-␥ production was not aff ected signifi cantly in the same setting, it is possible that IL-17F may regulate B cell responses to IFN-␥ , which is known to be important for IgG2a switching. B cells express the receptors for IL-17F (unpublished data). Whether they respond to IL-17F and what eff ect will be caused need to be investigated further. Nonetheless, our data suggest diff erential but clear involvement of IL-17 and IL-17F in the early phases of immune responses.
Evidence such as its presence in asthmatic CD4 T cell clones ( 22 ) or its mutations in asthma patients ( 45 ) suggests that their expression was dramatically decreased in IL-17F KO mice ( Fig. 7 D ) . Collectively, these data suggest that in intestinal infl ammation caused by DSS, IL-17 plays a protective role, whereas IL-17F may exacerbate the infl ammation.
DISCUSSION
Th17 and other IL-17 -expressing T cells have recently emerged as crucial regulators of infl ammatory responses. However, although IL-17 has been relatively well studied, the function of IL-17F is poorly understood. In this study, we describe the expression, signaling pathway, and in vivo function of IL-17F. Our study for the fi rst time indicates that although IL-17F has very similar regulation and function as IL-17 in vitro, analysis of animals defi cient in either of the two genes has revealed their distinct functions in infl ammatory responses.
IL-17F is expressed in Th17 cells and other types of IL-17 -expressing T cells in vivo. Previous papers describe similar regulation of IL-17 and IL-17F expression by cytokines IL-23, TGF-␤ , IL-6, and IL-21, as well as transcription factors ROR ␥ t, ROR ␣ , and STAT3 ( 8, 27 -29, 39, 40 ) . Moreover, we found that IL-17 and IL-17F gene promoters share the same pattern of chromatin remodeling in diff erentiated Th17 cells ( 15 ) . Several conserved noncoding sequences in this locus, including CNS2 ( 29 ), likely mediate the coordinated expression of IL-17 and IL-17F. However, our analysis also revealed diff erent ratios of IL-17 and IL-17F expression in diff erent T cell populations in vitro and in vivo. This suggests diff erential cytokine expression in diff erentiated Th17 cells. What accounts for this diff erential regulation is unknown at this point. The biological or pathological significance of this regulation is also unclear. In Th2 cells, we previously found that the inducible co-stimulator -c-Maf pathway only controls IL-4 but not IL-5 or IL-10 expression in the eff ector stage, and inducible co-stimulator defi ciency selectively abrogates IL-4 -dependent IgE production but not IL-5 -mediated airway eosinophilia ( 41, 42 ) . Moreover, expression of IL-22 by Th17 cells appears to be more dependent on IL-23 than IL-17 and IL-17F ( 43 ) . More studies are necessary in the future to comprehend the diff erential regulation of Th17 cytokines. Interestingly, our recent work revealed that ROR ␣ mutant T cells had a selective defect in IL-17 but not IL-17F or IL-22 production ( 29 ) .
Compared with IL-17, IL-17F has weaker activity in inducing proinfl ammatory molecules in vitro. However, this activity is meaningful as in vivo, transgenic overexpression of IL-17F led to pathological airway phenotypes. Why, then, do we need two similar cytokines? The situation is even more complex considering the heterodimeric IL-17A/F molecule with intermediate activity in vitro as compared with the IL-17 and IL-17F homodimers ( 16 ) . One possible explanation is that these cytokines may diff erentially use diff erent cytokine receptors that are diff erentially expressed or alternatively spliced. IL-17, IL-17F, and IL-17A/F depend on IL-17RA for signal transduction ( 16 ) . How IL-17RA mediates IL-17F signaling is unclear at this point. Previous literature showed that IL-17F did not bind to IL-17RA in vitro ( 18 ) . We also to generate MEFs using standard approaches. TRAF6 Ϫ / Ϫ MEFs were provided by T. Mak (University of Toronto, Toronto, Canada) and grown in high glucose DMEM supplemented with 10% FBS. For the measurement of IL-6 or CXCL1, cells were treated with cytokines overnight, and the culture supernatants were analyzed by ELISA. For RNA analysis, MEFs were treated for 4 h in serum-free DMEM before stimulation with various cytokines and homogenization in TRI zol (Invitrogen). RNA samples from IL-17F -treated Act1 -defi cient MEFs were provided by X. Li and C. Liu (Cleveland Clinic, Cleveland, OH). Lamina propria and intestinal intraepithelial lymphocytes were isolated from the small intestine as previously described ( 47 ) .
RT-PCR. cDNA was synthesized using RNase H RT (Invitrogen) analyzed in triplicates by using iQ SYBR Green Supermix in an iCycler (both from Bio-Rad Laboratories). The expression levels of each gene were normalized to the reference gene Actb expression level using a standard curve method. The primer sets for real-time PCR are as follows: IL-17F, (F) 5 Ј -CTGGAG-GATAACACTGTGAGAGT-3 Ј and (R) 5 Ј -TGCTGAATGGCGACG-GAGTTC-3 Ј . Other primers were described previously ( 3, 12, 36 ) .
Recombinant cytokine administration. IL-17R
Ϫ / Ϫ and WT mice were administered i.p. with 0.5 μ g of recombinant mouse IL-17 or IL-17F (R & D Systems) per mouse in 500 μ l of endotoxin-free PBS. The peritoneal lavage fl uid was carefully collected after 4 h. Cell pellets were resuspended in PBS/EDTA and total cell numbers were counted. Diff erential cell counting was performed on cytospin preparations stained with May-Gr ü nwald-Giemsa.
Generation of IL-17F transgenic mice.
To generate IL-17F transgenic mice, the CC10 promoter sequence (a gift from J. Elias, Yale University, New Haven, CT) was ligated to full-length mouse IL-17F cDNA followed by an internal ribosomal entry site (IRES) -GFP cassette (provided by K. Murphy, Washington University, St. Louis, MO). Human growth hormone intronic and polyadenylation sequences were inserted into the CC10 -IL-17F -IRES -GFP -pBluescript II construct using the Bam HI and Not I restriction enzyme sites. The IL-17F transgene construct was isolated by digestion with Not I and Sap I and was microinjected into B6 mice at the Transgenic Facility at the University of Washington. Three IL-17F transgenic founders were obtained and were maintained by breeding with B6 mice. Lungs were infused with 4% paraformaldehyde, and sections from these samples were made and stained with hematoxylin and eosin (H & E) and PAS. For immunohistochemistry, the lungs were infl ated with a 1:1 mixture of PBS/optimum cutting temperature (OCT) compound (Tissue-Tek; Sakura Finetek), embedded in OCT, and quickly frozen in a dry ice/isopropyl alcohol bath.
Generation of IL-17 and IL-17F KO mice. IL-17 -defi cient mice were generated by replacement of partial IL-17 exon 2 with a luciferase-IRESeGFP cassette without disrupting splicing boundaries, using the 129/TC1 embryonic stem cell line. The targeting vector applied NeoR as positive and thymidine kinase as negative selection markers. IL-17F KO was generated by insertion of an IRES-mRFP-polyA cassette into IL-17F exon 2. An Frtfl anked puromycin resistance gene and a diphtheria toxin gene served as positive and negative selection markers, respectively. Targeted embryonic stem clones for IL-17 or IL-17F were selected and injected into C57BL/6 blastocysts to generate chimeras. High percentage chimeras were bred with C57BL/6 for germline transmission. IL-17 +/ Ϫ mice were obtained after deletion of the NeoR cassette by crossing with the CMV-Cre strain, and IL-17F +/ Ϫ mice were obtained after excision of the PuroR cassette by crossing with FLPeR strain. Homozygous KO and WT animals on the same 129 × C57BL/6 F1 mixed background were bred and used in experiments. The genotyping primers for IL-17 KO were as follows: (F) 5 Ј -TCAACC-GTTCCACGTCACCCTGGAC -3 Ј and (R) 5 Ј -TCAGCATTCAACTT-GAGCTCTCATGC -3 Ј , amplifying a 299-bp WT band and/or a 414-bp KO band. The genotyping primers for IL-17F KO were as follows: (F) 5 Ј -ACATTGCCCACCACCAGGGCTC -3 Ј , (R1) 5 Ј -CCCATGGGGAA-CTGGAGCGGTTC -3 Ј , and (R2) 5 Ј -TTCGGCCAGTAACGTTAGG -3 Ј .
IL-17F might be relevant to asthma. Our current study using IL-17 and IL-17F KO animals indicates that IL-17 is not required for neutrophil recruitment in innate responses to an allergen; instead, IL-17F appears more prominent in recruiting neutrophils. However, when we examined the eff ect of IL-17 or IL-17F defi ciency on an asthma model, IL-17 KO mice, as predicted from the literature, exhibited reduced Th2 cytokine expression, whereas IL-17F KO mice had enhanced clinic symptoms such as elevated type 2 cytokines and eosinophil functions compared with WT mice. Thus, IL-17 and IL-17F may have opposite functions in chronic allergic airway diseases. The contrasting eff ects of IL-17 and IL-17F have also been observed in acute experimental colitis induced by DSS. IL-17F KO mice were protected, whereas IL-17 deficiency increased the colon damage. At this stage, it is diffi cult to comprehend the functional diff erences of IL-17 and IL-17F in these models. Perhaps the receptors for them are diff erentially expressed on target cells or these cytokines transduce diff erential signals that may, in turn, activate feedback antiinfl ammatory mechanisms. Further studies will be needed, and our data represent a fi rst step toward a better understanding of IL-17 and IL-17F functions in vivo.
In summary, in addition to IL-17, IL-17F is expressed in Th17 cells and IL-17 -expressing ␥ ␦ T cells. These two cytokines may use the same signaling components, such as IL-17RA, Act1, and TRAF6, to induce similar downstream infl ammatory genes. In vivo, transgenic overexpression of IL-17 or IL-I7F in the lung led to similar pathological phenotypes. However, our analysis using mice defi cient in either gene has revealed their distinct functions in diff erent types of infl ammatory responses. Our results have revealed complex mechanisms underlying tissue infl ammation. A further understanding of these mechanisms may shed light on cytokine targeting in the treatment of infl ammatory diseases such as allergic asthma and multiple sclerosis.
MATERIALS AND METHODS
Reagents.
Mouse IFN-␥ , IL-4, and IL-17 staining antibodies; IFN-␥ , IL-4, IL-17, and IL-6 ELISA antibodies; and CD4, CD8, B220, and isotype control antibodies used in immunohistochemistry analysis were purchased from BD Biosciences. CD11c antibody was purchased from Endogen. IL-6, TGF-␤ , IL-1 ␤ , and TNF-␣ were purchased from PeproTech, and LPS was obtained from Sigma-Aldrich. IL-23, IL-17, and IL-17F cytokines and ELISA antibodies for CXCL1 and IL-17F were obtained from R & D Systems. For the generation of IL-17F -Ig protein, cDNA sequences encoding IL-17F were amplifi ed by PCR and cloned into the DES-Ig vector ( 46 ) . The secreted Ig fusion proteins from stably transfected S2 cells were purifi ed by a protein A column after the CuSO 4 induction of fusion proteins expression. Polyclonal antibody against IL-17F was made by PRF & L by immunizing rabbits with purifi ed IL-17F -Ig fusion proteins.
Transient transfection. IL-17 and IL-17F cDNA were PCR amplifi ed and cloned into the pcDNA 3.1 + vector (Invitrogen), followed by sequencing confi rmation. 293T cells were transfected by calcium phosphate transfection.
Cell isolation and culture. Naive CD4 + T cells from OT-II mice purifi ed by AutoMACS (Miltenyi Biotec) were cultured at a ratio of 1:2 with irradiated B6 splenic APCs. Th1, Th2, and Th17 diff erentiation were performed as described previously ( 39 ) . IL-17R Ϫ / Ϫ mice obtained from Amgen were used
